Alpha Cognition Inc. (ACOG)
| Market Cap | 88.72M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -14.70M |
| Shares Out | 15.53M |
| EPS (ttm) | -2.66 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 134,716 |
| Open | 5.74 |
| Previous Close | 5.66 |
| Day's Range | 5.61 - 5.80 |
| 52-Week Range | 5.61 - 5.80 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 15, 2024 |
About ACOG
Alpha Cognition Inc., a clinical stage biopharmaceutical company, engages in the development of treatments for Alzheimer’s disease and amyotrophic lateral sclerosis (ALS). The company offers ZUNVEYL (benzgalantamine) for the treatment of mild-to-moderate Alzheimer’s disease and mild traumatic brain injury. It also develops ALPHA-0602, a gene therapy for the treatment of ALS; and ALPHA-0702 and ALPHA-0802, a granulin epithelin motifs for the treatment of neurodegenerative diseases. The company was formerly known as Crystal Bridge Enterprises Inc... [Read more]
News
Alpha Cognition Announces Financial Results for the Second Quarter and Six Months Ended June 2024 and Provides Corporate Update
VANCOUVER, British Columbia--(BUSINESS WIRE)--Alpha Cognition Inc. (NASDAQ: ACOG) (CSE: ACOG) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company developing novel therapeutics for debil...
Alpha Cognition Announces Pricing of $50 Million Upsized Public Offering and Nasdaq Listing
VANCOUVER, British Columbia--(BUSINESS WIRE)--Alpha Cognition Inc. (Nasdaq: ACOG) (CSE: ACOG) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company committed to developing novel therapies...